CN102526707A - 共刺激因子及融合蛋白的新用途 - Google Patents
共刺激因子及融合蛋白的新用途 Download PDFInfo
- Publication number
- CN102526707A CN102526707A CN2012100111486A CN201210011148A CN102526707A CN 102526707 A CN102526707 A CN 102526707A CN 2012100111486 A CN2012100111486 A CN 2012100111486A CN 201210011148 A CN201210011148 A CN 201210011148A CN 102526707 A CN102526707 A CN 102526707A
- Authority
- CN
- China
- Prior art keywords
- tumor
- cervical cancer
- medicine
- fusion rotein
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210011148.6A CN102526707B (zh) | 2012-01-13 | 2012-01-13 | 共刺激因子及融合蛋白的新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210011148.6A CN102526707B (zh) | 2012-01-13 | 2012-01-13 | 共刺激因子及融合蛋白的新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102526707A true CN102526707A (zh) | 2012-07-04 |
CN102526707B CN102526707B (zh) | 2015-04-22 |
Family
ID=46335522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210011148.6A Active CN102526707B (zh) | 2012-01-13 | 2012-01-13 | 共刺激因子及融合蛋白的新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102526707B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217750A (zh) * | 1996-05-04 | 1999-05-26 | 曾尼卡有限公司 | 抗cea的单克隆抗体,包括所述抗体的偶联物及其在adept系统中的治疗应用 |
CN101072578A (zh) * | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
-
2012
- 2012-01-13 CN CN201210011148.6A patent/CN102526707B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217750A (zh) * | 1996-05-04 | 1999-05-26 | 曾尼卡有限公司 | 抗cea的单克隆抗体,包括所述抗体的偶联物及其在adept系统中的治疗应用 |
CN101072578A (zh) * | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
Non-Patent Citations (3)
Title |
---|
郭建芬等: "共刺激分子在宫颈癌组织中的表达", 《中华医学杂志》, vol. 80, no. 5, 31 May 2000 (2000-05-31), pages 342 - 345 * |
陶光实等: "共刺激分子B7基因诱导小鼠抗子宫颈癌主动免疫的研究", 《中华妇产科杂志》, vol. 36, no. 2, 28 February 2001 (2001-02-28), pages 111 - 114 * |
陶光实等: "转染B7基因的U14疫苗对小鼠宫颈癌的防治作用研究", 《现代妇产科进展》, vol. 12, no. 4, 31 July 2003 (2003-07-31), pages 241 - 244 * |
Also Published As
Publication number | Publication date |
---|---|
CN102526707B (zh) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Uchida et al. | Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus | |
Sayour et al. | Manipulation of innate and adaptive immunity through cancer vaccines | |
CN102101888B (zh) | 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法 | |
AU2018378395B2 (en) | Nucleotide sequence encoding car, ROBO1 CAR-NK cell expressing car and preparation therefor and use thereof | |
JP2019528753A5 (zh) | ||
CN107557336A (zh) | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 | |
CN106554416B (zh) | 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白(sting)激动剂在抗肿瘤中的应用 | |
CN108165536A (zh) | 一种重组溶瘤痘苗病毒及其制备方法与应用 | |
Minton | Intestinal barrier protection | |
Bird | Magnesium: essential for T cells | |
CN107164412A (zh) | 一种安全型抗cea嵌合抗原受体修饰t细胞的制备方法及其应用 | |
WO2021062332A1 (en) | Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer | |
CN107541499A (zh) | 一种靶向免疫检测点tnfr2的cik的制备及其应用 | |
CN102526707B (zh) | 共刺激因子及融合蛋白的新用途 | |
CN113117088B (zh) | 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用 | |
CN102526708A (zh) | 共刺激因子在癌症治疗方面的新用途 | |
CN113750239B (zh) | 一种用于治疗宫颈癌的药物组合物及其药物制剂和应用 | |
CN109735571A (zh) | 双自杀基因慢病毒表达载体及其应用 | |
CN103882057A (zh) | 携带p21ras单链抗体基因肿瘤特异性腺病毒载体的构建及其应用 | |
CN104357466B (zh) | 一种单纯疱疹病毒胸苷激酶突变体及其制备方法和用途 | |
CN107630005A (zh) | 表达plac1特异性tcr的t细胞及其应用 | |
CN107335056A (zh) | Nkila作为靶点在筛选或制备治疗肿瘤的药物中的用途 | |
CN106336456A (zh) | 一种cd33免疫原多肽及其用途 | |
CN114014938B (zh) | 一种嵌合抗原受体(car)及其应用 | |
CN101396554A (zh) | 重组人干扰素γ在制备抗病毒药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181010 Address after: 725000 Shaanxi Ankang hi tech Industrial Development Zone Science and technology road Patentee after: Ankang Bei Yi Da Biological Medicine Co., Ltd. Address before: 610041 16 Chuang Road, high tech Avenue, Chengdu, Sichuan Co-patentee before: Xizang Tianxing Biomedical Co., Ltd. Patentee before: Chengdu Bofa Biotechnology Co., Ltd. Co-patentee before: Tianjin Bofa Biotechnology Co., Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 710000 science and technology road, high tech Industrial Development Zone, Ankang City, Shaanxi Province Patentee after: Shaanxi jinsiming Biotechnology Co., Ltd Address before: 725000 Shaanxi Ankang hi tech Industrial Development Zone Science and technology road Patentee before: Ankang Bei Yi Da Biological Medicine Co., Ltd. |